Clinical Focus: Current Approaches to the Treatment of Hormone Receptor–Positive, HER2-Negative Metastatic Breast Cancer

Denise A. Yardley, MD, explores current treatment options for hormone receptor–positive, HER2-negative metastatic breast cancer.
person default
Denise A. Yardley, MD
Physicians: maximum of 1.0 AMA PRA Category 1 Credit
Released: January 15, 2013 Expiration: January 14, 2014

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Plan treatment strategies based on key data from clinical trials of approaches targeting multiple pathways in hormone receptor–positive, HER2-negative metastatic breast cancer
  • Discuss the opportunity to participate in clinical trials with appropriate eligible patients with hormone receptor–positive, HER2-negative metastatic breast cancer

Acknowledgements

Jointly sponsored by Postgraduate Institute for Medicine and Clinical Care Options, LLC
PIM Logo

Postgraduate Institute for Medicine
304 Inverness Way South, Suite 100
Englewood, CO 80112

Allison Hughes, CCMEP, Program Manager
(303) 799-1930
(303) 858-8842 (Fax)
ahughes@pimed.com
www.pimed.com

Educational grant provided by:
Novartis Pharmaceuticals Corporation

Information on this Educational Activity

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) assesses conflict of interest with its instructors, planners, managers, and other individuals who are in a position to control the content of CME activities. All relevant conflicts of interest that are identified are thoroughly vetted by PIM for fair balance, scientific objectivity of studies utilized in this activity, and patient care recommendations. PIM is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Faculty

Denise A. Yardley, MD

Senior Investigator
Breast Cancer Research Program
The Sarah Cannon Research Institute and Tennessee Oncology
Nashville, Tennessee

Denise A. Yardley, MD, has no significant financial relationships to disclose.

Staff

Andrew D. Bowser, ELS, CCMEP

Editorial Director, Hematology/Oncology

Andrew D. Bowser, ELS, CCMEP, has no significant financial relationships to disclose.
Gordon Kelley

Senior Clinical Editor

Gordon Kelley has no significant financial relationships to disclose.
Edward King, MA

Chief Innovation Officer

Edward King, MA, has no significant financial relationships to disclose.
David Modrak, PhD

Managing Editor

David Modrak, PhD, has no significant financial relationships to disclose.
Jim Mortimer

Senior Director, Oncology Programs and Partnership Development

Jim Mortimer has no significant financial relationships to disclose.

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

The following PIM planners and managers, Laura Excell, ND, NP, MS, MA, LPC, NCC; Trace Hutchison, PharmD; Samantha Mattiucci, PharmD; Jan Schultz, RN, MSN, CCMEP; and Patricia Staples, MSN, NP-C, CCRN, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Postgraduate Institute for Medicine (PIM) and Clinical Care Options, LLC and do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of PIM and Clinical Care Options, LLC. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Target Audience

This program is intended for physicians and other healthcare professionals who provide care for patients with metastatic breast cancer.

Goal

The goal of this activity is to provide participants with therapeutic strategies that integrate emerging clinical trial data to improve outcomes for patients with hormone receptor–positive, HER2-negative metastatic breast cancer.

Physician Continuing Medical Education

Accreditation Statement

This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of Postgraduate Institute for Medicine and Clinical Care Options, LLC. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1.0 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from January 15, 2013, through January 14, 2014:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Related Content

Download these slides on treatment strategies for HER2+ EBC to review the most recent data on using trastuzumab/pertuzumab, T-DM1, and neratinib.

Sara Hurvitz, MD, FACP Hope S. Rugo, MD Released: April 25, 2019

Expert commentary from CCO on choosing specific CDK4/6 inhibitors using differences in safety and patient presentation characteristics.

Matthew P. Goetz, MD Released: March 29, 2019

Download this CME-certified slideset with expert analysis on key studies in early and locally advanced/metastatic breast cancer from the 2018 SABCS annual meeting.

Mohammad Jahanzeb, MD, FACP Physicians: maximum of 1.0 AMA PRA Category 1 Credit Released: January 23, 2019 Expiration: January 22, 2020

Read expert answers to audience questions on the use of PARP inhibitors for the treatment of breast cancer from a CCO symposium at SABCS 2018.

Mark E. Robson, MD Released: January 10, 2019

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.

Continue

More info

CCO’s educational programs are available completely free of charge on the ClinicalOptions.com, inPractice.com, and inPracticeAfrica.com Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?